SVB Leerink Starts Trevi Therapeutics (TRVI) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
Go back to SVB Leerink Starts Trevi Therapeutics (TRVI) at Outperform
June 3, 2019 7:16 AM EDT
Stifel analyst Annabel Samimy initiates coverage on Trevi Therapeutics (NASDAQ: TRVI) with a Buy rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Trevi Therapeutics click here. For more ratings news on Trevi Therapeutics click here.
Shares of Trevi Therapeutics closed at $9.99 yesterday.
...
More
June 3, 2019 7:12 AM EDT
Needham & Company analyst Serge Belanger initiates coverage on Trevi Therapeutics (NASDAQ: TRVI) with a Buy rating and a price target of $18.00.
The analyst comments "We are initiating coverage of Trevi Therapeutics (TRVI), a clinical-stage biopharma focused on the development of oral... More
June 3, 2019 2:18 AM EDT
BMO Capital analyst Gary Nachman initiates coverage on Trevi Therapeutics (NASDAQ: TRVI) with a Outperform rating and a price target of $15.00.
The analyst comments "Key product Nalbuphine ER has a solid track record and substantial evidence supporting its mechanism to treat various chronic... More
